$PAVM

PAVmed (NASDAQ: PAVM) Scott Dols reports 5.4% stake, 346,155 shares

Scott V. Dols has reported a beneficial ownership of 346,155 shares, representing a 5.4% stake in PAVmed Inc. (NASDAQ: PAVM). This disclosure was made via a Schedule 13G SEC filing, based on 6,383,089 shares outstanding as of March 27, 2026. Dols holds sole voting and dispositive power over these shares, which include 230,770 shares held in a trust where he serves as trustee.

Original reporting
Published Apr 9, 2026, 5:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 9, 2026, 5:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$PAVM
Bullish
medium confidence
Mentioned
$PAVM
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$PAVMBullishMed
01

Why it matters

The increased insider stake could be perceived as a vote of confidence, potentially boosting investor confidence and stock price.

02

Market read

The insider stake disclosure is relevant for investors monitoring insider activity and company confidence signals.

03

What to watch

Market conditions, overall sector performance, and company fundamentals should be considered before acting on insider activity.

Timing: Immediate, as the disclosure is recent and may influence trading decisions.

Background

Scott Dols' disclosure of a 5.4% stake in PAVmed Inc. was made via a Schedule 13G SEC filing, indicating passive ownership and not necessarily strategic control.

Company-level read

Ticker impact

$PAVMBullishMedium confidence
Context

The reported 5.4% ownership stake by Scott Dols in PAVmed Inc. indicates a significant insider position, which could influence market perception.

Expected impact

Moderate upward price movement expected over the short to medium term.

Evidence & confidence

Insider ownership changes can influence investor sentiment; however, as this is a passive disclosure without additional strategic actions, the impact may be limited.

Market effects

Potential positive sentiment for biotech and healthcare sectors, especially companies with active insider trading or ownership disclosures.

Limited, as the news pertains specifically to a U.S.-listed company and insider activity.

Minimal, unless PAVmed Inc. is part of a broader industry trend or strategic move.

Counterpoint

Insider ownership increases do not always translate to positive market performance; some insiders may acquire shares for reasons unrelated to company prospects.

Key entities

  • Scott V. Dols

    Investor who reported a 5.4% stake in PAVmed Inc.

  • PAVmed Inc.

    NASDAQ-listed medical device and digital health company.

Related articles

$PAVMMed

PAVmed (PAVM) Q2 2026 Earnings Call Transcript

PAVmed (PAVM) held its Q2 2026 earnings call. GAAP net loss was $5.5 million ($0.87/share) and non-GAAP adjusted loss was $1.7 million ($0.27/share). Revenue was $33,000, with pro forma income over $3 million. Cash was $3.8 million at June 30. Management discussed Veris, Lucid Diagnostics, and device regulatory timelines, including a targeted early-2027 510(k) submission for Veris.

$PAVMMed

PAVmed Inc. (PAVM): Results of Operations and Financial Condition

PAVmed Inc. (PAVM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Luci

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.